The American Society of Clinical Oncology published two clinical practice guidelines on treating women with advanced, HER2-positive breast cancer.

Neratinib combined with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer.

Researchers concluded that the MammaPrint genomic breast cancer test can accurately stratify a woman's breast cancer risk for up to 25 years after she is first diagnosed with the disease.

Contrary to existing understanding, long-term follow-up of patients with two types of breast tissue abnormalities suggests that both types of abnormalities have the same potential to progress to breast cancer.